Technology | Leads Implantable Devices | March 04, 2016

Boston Scientific Receives FDA Approval for Acuity X4 Quadripolar Leads

Left ventricular leads to be used in trial pursuing MRI labeling for cardiac defibrillation and resynchronization systems

Boston Scientific, Acuity X4 quadripolar left ventricular leads, FDA approval, ENABLE MRI study

March 4, 2016 — Boston Scientific has received U.S. Food and Drug Administration (FDA) approval for the Acuity X4 quadripolar left ventricular (LV) leads. The FDA approval of the quadripolar leads, the wires that connect cardiac resynchronization therapy (CRT) devices to the heart, marks the first time the company will offer a full X4 CRT system – both the device and the leads – to the U.S. market.

The family of Acuity X4 quadripolar LV leads is engineered with four electrodes along a unique 3-D shape. The leads are designed to enable physicians to place them in the vasculature easily and to allow pacing at an optimal site to improve the patient response to CRT therapy.

FDA approval of the leads was based on data from the NAVIGATE X4 study, a prospective, non-randomized, multicenter clinical trial that enrolled 764 patients. The study successfully met the primary safety and efficacy endpoints through six months of follow-up.

"Data collected in the NAVIGATE X4 study demonstrate that these leads are safe and effective for use with CRT devices," said Suneet Mittal, M.D., principal investigator, director of the electrophysiology laboratory for Valley Hospital Health System in Ridgewood, N.J. "The approval is a testament to the strength of the data in this trial, which also demonstrated fast lead implant times, stable lead placement and improved pacing performance resulting from the unique design of the Acuity X4 leads."

Earlier this month, the company initiated the global ENABLE MRI study, which is intended to support FDA approval for magnetic resonance imaging (MRI) across the company's currently approved implanted cardiac defibrillation (ICD) and CRT systems. The newly approved family of Acuity X4 quadripolar LV leads will be used in this study, which is expected to enroll as many as 500 patients at approximately 60 sites worldwide. Trial findings will be submitted to regulatory authorities in Asia and the United States when the company requests updated labeling for MRI-conditional use on ICD and CRT systems, including those that have previously been implanted.

The MRI-conditional labeling in the U.S. would include current and future families of Extended Longevity (EL) and Mini ICDs and the X4 cardiac resynchronization therapy defibrillator (CRT-D) systems, including leads. In August of 2015, the company received CE Mark on MRI conditional labeling on its EL and Mini ICDs and X4 CRT-D systems, as well as the Acuity X4 quadripolar LV leads, Ingevity and Fineline II pacing leads and Reliance 4-Site and 4-Front defibrillator leads. The X4 line of CRT-Ds includes the Dynagen X4 and Inogen X4 in the U.S.

For more information: www.bostonscientific.com

Related Content

Abbott Announces MR-Conditional Labeling for Quadra Assura CRT-D and Fortify Assura ICD
Technology | Cardiac Resynchronization Therapy Devices (CRT) | January 03, 2018
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT) | August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT) | July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
Videos | Cardiac Resynchronization Therapy Devices (CRT) | May 23, 2017
This video, provided by ERB, demonstrates the function and implantation of the WiSE CRT (Wireless Stimulation Endocar
Biotronik Announces FDA Approval of MultiPole Pacing
Technology | Cardiac Resynchronization Therapy Devices (CRT) | May 11, 2017
May 11, 2017 — Biotronik announced U.S.
Biotronik Launches First FDA-Approved CRM Devices with MRI AutoDetect Technology
Technology | Cardiac Resynchronization Therapy Devices (CRT) | May 10, 2017
Biotronik announced the availability of the first U.S. Food and Drug Administration (FDA)-approved cardiac rhythm...
NICE Recommends Boston Scientific CRT-Ds With EnduraLife Battery Technology for Heart Failure Treatment
News | Cardiac Resynchronization Therapy Devices (CRT) | April 14, 2017
The National Institute for Health and Care Excellence (NICE) recently issued medical technology guidance recommending...
Biotronik, Edora series, pacemakers, CRT-Ps
Technology | Cardiac Resynchronization Therapy Devices (CRT) | March 23, 2017
March 23, 2017 — Biotronik announced the European launch of the Edora series, its smallest series of...
Overlay Init